Roche Holding is a Switzerland-based healthcare group with both pharmaceuticals and diagnostics divisions. It is included here because Roche Pharmaceuticals researches, develops and commercializes innovative treatments, not because its diagnostics business alone qualifies. Corporate material highlights areas including oncology, neuroscience, immunology, ophthalmology, and cardiovascular and metabolic diseases. The company also offers multiple classes of securities, including Swiss bearer shares and participation certificates and an OTC-traded American depositary receipt. These instruments should be represented under one legal issuer rather than as independent biotechnology companies.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Roche Holding is a Switzerland-based healthcare group with both pharmaceuticals and diagnostics divisions. It is included here because Roche Pharmaceuticals researches, develops and commercializes innovative treatments, not because its diagnostics business alone qualifies. Corporate material highlights areas including oncology, neuroscience, immunology, ophthalmology, and cardiovascular and metabolic diseases. The company also offers multiple classes of securities, including Swiss bearer shares and participation certificates and an OTC-traded American depositary receipt. These instruments should be represented under one legal issuer rather than as independent biotechnology companies.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
On 2026-06-08, Roche announced joint development and commercialization with Nurix of the oral BTK degrader bexobrutideg (NX-5948), with CLL Phase 3 planned for summer 2026.
Business, technology & evidence
Nurix's 2026-10-12 update confirms first enrollment in Phase 3 DAYBreak CLL-306 for the same NX-5948 asset.
Roche Holding is a Switzerland-based healthcare group with both pharmaceuticals and diagnostics divisions. It is included here because Roche Pharmaceuticals researches, develops and commercializes innovative treatments, not because its diagnostics business alone qualifies. Corporate material highlights areas including oncology, neuroscience, immunology, ophthalmology, and cardiovascular and metabolic diseases. The company also offers multiple classes of securities, including Swiss bearer shares and participation certificates and an OTC-traded American depositary receipt. These instruments should be represented under one legal issuer rather than as independent biotechnology companies.
SecuritiesSIX: RO / SIX: ROP / OTCQX: RHHBY
Program / service
Target / indication
Representative stage
Evidence & scope
bexobrutideg / NX-5948
BTK · B-cell malignancies including CLL/SLL
Phase 3
Clinical data available; no cross-trial comparison is made here
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Roche entered a research collaboration and licensing agreement with Hangzhou-based Defand Therapeutics to discover molecular glue degraders for oncology and immunology targets. Defand will contribute its screening platform, with Roche taking responsibility for subsequent development and exclusive global commercialization. The announcement did not disclose upfront payment amounts, milestone thresholds, or royalty rates.
Nurix announced the first patient enrollment in NX-5948-203, a Phase 1b/2 trial combining the investigational BTK degrader bexobrutideg with venetoclax in chronic lymphocytic leukemia. Initial enrollment focuses on relapsed or refractory disease. Conducted under the Roche collaboration, the study will assess safety, tolerability, and clinical activity to inform potential combination development across treatment settings.
Phase 3 timing in the original announcement was a plan and does not confirm actual initiation. This is the same asset as Nurix's and should be deduplicated.
